View Exam | PowerPak

1. Which of the following biomarkers is currently incorporated into product label indications for anti-PD-1/PD-L1 drug use in specific designated tumor types?

A. Programmed death-ligand 1 (PD-L1) B. Deficient mismatch repair (dMMR) C. Tumor mutation burden (TMB) D. Microsatellite instability-high (MSI-H) E. Unsure

2. Which of the following biomarkers is associated with an agnostic indication for anti-PD-1/PD-L1 immunotherapies?

A. Programmed death-ligand 1 (PD-L1) expression B. Deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) C. Tumor mutation burden (TMB) D. Programmed cell death protein 1 (PD-1) expression E. Unsure

3. Which of the following laboratory test methodologies can be used to determine both tumor programmed death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB)?

A. Next-generation sequencing B. Immunohistochemistry C. Polymerase chain reaction D. Flow cytometry E. Unsure

4. A patient with an excellent performance status and diagnosed with metastatic non-small cell lung cancer undergoes a tissue biopsy. Laboratory testing reveals: absence of EGFR activating mutations, negative ALK gene rearrangement/fusions, wild-type ROS1 and BRAF, and programmed death-ligand 1 (PD-L1) positivity >50%. Which of the following initial treatments is most appropriate?

A. EGFR inhibitor B. ALK inhibitor C. BRAF inhibitor D. Pembrolizumab E. Unsure

5. Prior to 2018, the Centers for Medicare and Medicaid “14 Day Rule” had which of the following impacts on independent labs when billing for services?

A. Labs could only bill for a service if the service was ordered less than 14 days from the specimen being collected and/or 14 days from a patient's hospital discharge date B. Labs could only bill for a service if the service was ordered more than 14 days from the specimen being collected and/or 14 days from a patient's hospital discharge date C. Labs were not allowed to bill for any molecular pathology tests D. The rule only impacted hospital pathology departments and did not impact external labs E. Unsure

6. According to Dr. Oxnard, what patient information should be gathered to inform treatment decisions for patients with non-small cell lung cancer in which immuno-oncology therapy may be a treatment option?

A. Programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) test alone B. PD-1 or PD-L1 test alone and smoking history C. PD-1 or PD-L1 test alone, smoking history, and genotype testing for EGFR or ALK D. Genotype testing for EGFR or ALK alone E. Unsure

Evaluation Questions

7. How confident are you in your decision about treatment for the patient in the question above?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following biomarkers is currently incorporated into product label indications for anti-PD-1/PD-L1 drug use in specific designated tumor types?

2. Which of the following biomarkers is associated with an agnostic indication for anti-PD-1/PD-L1 immunotherapies?

3. Which of the following laboratory test methodologies can be used to determine both tumor programmed death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB)?

5. Prior to 2018, the Centers for Medicare and Medicaid “14 Day Rule” had which of the following impacts on independent labs when billing for services?

6. According to Dr. Oxnard, what patient information should be gathered to inform treatment decisions for patients with non-small cell lung cancer in which immuno-oncology therapy may be a treatment option?

Evaluation Questions

7. How confident are you in your decision about treatment for the patient in the question above?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following biomarkers is currently incorporated into product label indications for anti-PD-1/PD-L1 drug use in specific designated tumor types?

2. Which of the following biomarkers is associated with an agnostic indication for anti-PD-1/PD-L1 immunotherapies?

3. Which of the following laboratory test methodologies can be used to determine both tumor programmed death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB)?

5. Prior to 2018, the Centers for Medicare and Medicaid “14 Day Rule” had which of the following impacts on independent labs when billing for services?

6. According to Dr. Oxnard, what patient information should be gathered to inform treatment decisions for patients with non-small cell lung cancer in which immuno-oncology therapy may be a treatment option?

Evaluation Questions

7. How confident are you in your decision about treatment for the patient in the question above?

« Return to Activity

Customers who Purchased
this Activity also Purchased